SWOG clinical trial number
CTSU/A011502

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

Open
Phase
Abbreviated Title
The ABC Trial: Rando PIII Double Blind Placebo/Aspirin for Node+ / HER2- Breast Cancer
Status Notes
This study is active in SWOG effective 4/15/17.
Activated
04/15/2017
Participants
CTSU

Research committees

Breast Cancer

Treatment

Aspirin

Eligibility Criteria Expand/Collapse

SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.

Publication Information Expand/Collapse

2024

Association of Higher baseline stress and pain associated with clinical outcomes: A secondary analysis from Alliance A011502

S Gandhi;K Ballman;M Holmes;K Visvanathan;B Symington;M Carvan;C Matyka;A Weiss;E Winer;L Carey;A Partridge;W Chen ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), Rapid Oral Abstract Session; J Clin Oncol 42, 2024 (suppl 16; abstr 11016)

Correlation of Stress, depression, sleep, and pain vary with race and BMI: Secondary analysis from A011502

S Gandhi;K Ballman;M Holmes;K Visvanathan;B Symington;M Carvan;C Matyka;A Weiss;E Winer;L Carey;A Partridge;W Chen ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), publication only; J Clin Oncol 42, 2024 (suppl 16; abstr e23171)

Other Clinical Trials

SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
9%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
16%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase